Journal article
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
SM de Boer, ME Powell, L Mileshkin, D Katsaros, P Bessette, C Haie-Meder, PB Ottevanger, JA Ledermann, P Khaw, A Colombo, A Fyles, MH Baron, IM Jürgenliemk-Schulz, HC Kitchener, HW Nijman, G Wilson, S Brooks, S Carinelli, D Provencher, C Hanzen Show all
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2018
Abstract
Background: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. Methods: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascula..
View full abstractGrants
Funding Acknowledgements
Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council Project Grant and Cancer Australia, L'Agenzia Italiana del Farmaco, and Canadian Cancer Society Research Institute.